CClinicalTrials.gg
WithdrawnNCT00313118Updated Mar 28, 2017

Mean Values of Oxidative Stress Parameters in Healthy Subjects

An observational study in Healthy, sponsored by Selim Orguel. Withdrawn at 1 site in Switzerland. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-03-28.

Sponsored by Selim Orguel · Observational

Why this study was withdrawn
Problems with recruiting
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
0
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Determination of the mean value of oxidative stress parameters in normals and of the plasma and serum levels, resp. of malondialdehyde, glutathion and superoxide dismutase in healthy subjects.

Read the detailed description

In certain situations, free radicals can be generated in an exaggerated manner and can injure tissues and organs by interacting with lipids, proteins, or DNA. So, oxidative stress has been implicated in a large number of human diseases. To survive, the human body has developed a complex, efficient, and highly adaptive antioxidant defense system. The eye is also protected against oxidative stress by several mechanisms involving antioxidant enzymes such as catalase (CAT) and superoxide dismutase (SOD), as well as by low-molecular-weight antioxidants such as glutathion (GSH) and ascorbate.

Primary open-angle glaucoma (POAG) is a chronic, slowly progressive optic neuropathy, characterized by excavation of the optic nerve head (ONH) and a distinctive pattern of visual field (VF) defects. The disease is multifactorial in origin, so that besides more extensively investigated factors oxidative stress has also been proposed as a contributing factor in the etiology of glaucomatous optic neuropathy. Oxidative stress represents a harmful state defined by the presence of pathologic levels of reactive oxygen species (ROS) relative to antioxidant defense.

Therefore, it would be also important to determine whether there is a relationship between circulating levels of the defense parameters to oxidative stress like malondialdehyde, GSH and SOD, and the occurrence of POAG.

Since there are only the limits of variation for these defense parameters available, mean values of the plasma levels of malondialdehyde, glutathion and superoxide dismutase will be determined in healthy subjects.

02

Conditions studied

  • Healthy

Keywords

  • oxidative stress parameters
03

In context

Lead sponsor

Selim Orguel is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

healthy persons

Inclusion criteria

  • German native speakers
  • Age between 18-80 years
  • Healthy without medication
  • No ophthalmic disease

Exclusion criteria

Exclusion Criteria:

  • Any history of ocular or systemic diseases or of drug or alcohol abuse
  • Any mentally impaired patient
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
0 participants (actual)
Biospecimen retention
None retained
06

Study locations

1 site
  • University Eye Clinic Basel
    Basel, BS 4031, Switzerland
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00313118
Lead sponsor
Selim Orguel
Collaborators
Laboratory Dr. Bayer GmbH, Stuttgart, Germany
Responsible party
Selim Orguel (Prof. Dr., University Hospital, Basel, Switzerland) — Sponsor-investigator
First posted
Apr 11, 2006
Start date
Jan 2006
Primary completion
Sep 2010
Completion
Dec 2016
Last update
Mar 28, 2017

Study contacts

Selim Orgül, MD
study director · University Hospital, Basel, Switzerland

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion